IP Library Granted Patent US 11,638,715
Granted Patent B2
US 11,638,715 · App. 17/842,402 · Granted May 2, 2023

Orally-bioavailable nucleoside analogs

Inventors: Christopher J. Burns (Malvern, PA); Glen Coburn (Bethel, CT); Guo-Hua Chu (Exton, PA); Stephen M. Condon (Glenmoore, PA); Steven A. Boyd (Chester Springs, PA); Daniel C. Pevear (Downingtown, PA)
Assignee: VENATORX PHARMACEUTICALS, INC.
A61K31/7076A61K9/0053A61K9/2018A61K9/2054A61K9/2059A61K9/4858A61K31/53A61K31/675A61K31/685A61K31/7072C07D487/04C07F9/6561C07H19/06C07H19/10C07H19/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,638,715
App. No.
17/842,402
Granted
May 2, 2023
Kind
B2
Abstract

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Claims (71)

1. A compound of Formula (II), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:

wherein:

X is hydrogen or —CN;

G is

R 11 is hydrogen, —C(═O)R 21 , —C(═O)OR 21 , or C 1 -C 6 alkyl optionally substituted with one or more R 11a ;

each R 11a is independently halogen, —CN, —OH, —OR a , —NR c R d , cycloalkyl, or heterocycloalkyl;

or two R 11a on the same atom are taken together to form an oxo;

R 21 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene(cycloalkyl), C 1 -C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 21a ;

each R 21a is independently halogen, —CN, —NO 2 , —OH, —OR a , —OC(═O)R a , —OC(═O)OR b , —OC(═O)NR c R d , —S(═O)R a , —S(═O) 2 R a , —S(═O) 2 NR c R d , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R;

or two R 21a on the same atom are taken together to form an oxo;

or two R 21a are taken together to form a cycloalkyl or heterocycloalkyl; each optionally and independently substituted with one or more R;

R 12 is hydrogen, —C(═O)R 22 , —C(═O)OR 22 , or C 1 -C 6 alkyl optionally substituted with one or more R 12a ;

each R 12a is independently halogen, —CN, —OH, —OR a , —NR c R d , cycloalkyl, or heterocycloalkyl;

or two R 12a on the same atom are taken together to form an oxo;

R 22 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene(cycloalkyl), C 1 -C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 22a ;

each R 22a is independently halogen, —CN, —NO 2 , —OH, —OR a , —OC(═O)R a , —OC(═O)OR b , —OC(═O)NR c R d , —S(═O)R a , —S(═O) 2 R a , —S(═O) 2 NR c R d , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R;

or two R 22a on the same atom are taken together to form an oxo;

or two R 22a are taken together to form a cycloalkyl or heterocycloalkyl; each optionally and independently substituted with one or more R;

R 13 is hydrogen or C 1 -C 6 alkyl;

R 14 is —OH or fluoro;

R 15 is hydrogen, —C(═O)R 25 , —C(═O)OR 25 , —CH 2 —O—C(═O)R 25 , —CH 2 —O—C(═O)OR 25 , or C 1 -C 6 alkyl optionally substituted with one or more R 15a ;

each R 15a is independently halogen, —CN, —OH, —OR a , —NR c R d , cycloalkyl, or heterocycloalkyl;

or two R 15a on the same atom are taken together to form an oxo;

R 25 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene(cycloalkyl), C 1 -C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl); wherein the alkyl, alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 25a ;

each R 25a is independently halogen, —CN, —NO 2 , —OH, —OR a , —OC(═O)R a , —OC(═O)OR b , —OC(═O)NR c R d , —S(═O)R a , —S(═O) 2 R a , —S(═O) 2 NR c R d , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R;

or two R 25a on the same atom are taken together to form an oxo;

or two R 25a are taken together to form a cycloalkyl or heterocycloalkyl; each optionally and independently substituted with one or more R;

R 16 is —C(═O)R 26 , —C(═O)OR 26 , —CH 2 —O—C(═O)R 26 , or —CH 2 —O—C(═O)OR 26 ;

R 26 is C 1 -C 6 alkylene(cycloalkyl), C 1 -C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl); wherein the alkylene, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally and independently substituted with one or more R 26a ;

each R 26a is independently halogen, —CN, —NO 2 , —OH, —OR a , —OC(═O)R a , —OC(═O)OR b , —OC(═O)NR c R d , —SH, —SR a , —S(═O)R a , —S(═O) 2 R a , —S(═O) 2 NR c R d , —NR c R d , —NR b C(═O)NR c R d , —NR b C(═O)R a , —NR b C(═O)OR b , —NR b S(═O) 2 R a , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;

or two R 26a on the same atom are taken together to form an oxo;

or two R 26a on the same carbon are taken together to form a cycloalkyl or heterocycloalkyl; each optionally substituted with one or more R;

each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkyl(cycloalkyl), C 1 -C 6 alkyl(heterocycloalkyl), C 1 -C 6 alkyl(aryl), or C 1 -C 6 alkyl(heteroaryl), wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

each R b is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkyl(cycloalkyl), C 1 -C 6 alkyl(heterocycloalkyl), C 1 -C 6 alkyl(aryl), or C 1 -C 6 alkyl(heteroaryl), wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

R c and R d are each independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 heteroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkyl(cycloalkyl), C 1 -C 6 alkyl(heterocycloalkyl), C 1 -C 6 alkyl(aryl), or C 1 -C 6 alkyl(heteroaryl), wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;

or R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; and

each R is independently halogen, —CN, —OH, —OCH 3 , —S(═O)CH 3 , —S(═O) 2 CH 3 , —S(═O) 2 NH 2 , —S(═O) 2 NHCH 3 , —S(═O) 2 N(CH 3 ) 2 , —NH 2 , —NHCH 3 , —N(CH 3 ) 2 , —C(═O)CH 3 , —C(═O)OH, —C(═O)OCH 3 , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, and C 1 -C 6 heteroalkyl;

or two R on the same atom are taken together to form an oxo; provided that when G is

and X is —CN, or G is

and X is hydrogen; then at least one of R 11 , R 12 or R 15 is not hydrogen.

2. The compound of claim 1 , wherein G is

3. The compound of claim 1 , wherein G is

4. The compound of claim 1 , wherein R 11 is hydrogen.

5. The compound of claim 1 , wherein R 12 is hydrogen, —C(═O)R 22 , —C(═O)OR 22 , or C 1 -C 6 alkyl.

6. The compound of claim 1 , wherein R 12 is —C(═O)R 22 , —C(═O)OR 22 , or C 1 -C 6 alkyl.

7. The compound of claim 1 , wherein R 22 is C 1 -C 6 alkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C 1 -C 6 alkylene(cycloalkyl), C1-C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl).

8. The compound of claim 1 , wherein R 22 is C 1 -C 6 alkyl, C 1 -C 6 aminoalkyl, aryl, C 1 -C 6 alkylene(cycloalkyl), C 1 -C 6 alkylene(heterocycloalkyl), C 1 -C 6 alkylene(aryl), or C 1 -C 6 alkylene(heteroaryl).

9. The compound of claim 1 , wherein R 22 is C 1 -C 6 alkyl, C 1 -C 6 aminoalkyl, aryl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(aryl).

10. The compound of claim 1 , wherein R 22 is C 1 -C 6 alkyl or C 1 -C 6 alkylene(aryl); wherein the alkyl, alkylene, and aryl is optionally and independently substituted with one or more R 22a .

11. The compound of claim 1 , wherein each R 22a is independently halogen, —CN, —OH, —OR a , —OC(═O)R a , —OC(═O)OR b , —OC(═O)NR c R d , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

12. The compound of claim 1 , wherein each R 22a is independently halogen, —CN, —OH, —OR a , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

13. The compound of claim 1 , wherein each R 22a is independently halogen, —OH, —OR a , —NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

14. The compound of claim 1 , wherein each R 22a is independently halogen, —OC(═O)R a , or —NR c R d .

15. The compound of claim 1 , wherein R 15 is hydrogen or —C(═O)R 25 .

16. The compound of claim 1 , wherein R 15 is —C(═O)R 25 .

17. The compound of claim 1 , wherein R 25 is C 1 -C 6 alkyl, C 1 -C 6 aminoalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(aryl); wherein the alkyl, alkylene, cycloalkyl, and aryl, is optionally and independently substituted with one or more R 25a .

18. The compound of claim 1 , wherein R 25 is C 1 -C 6 alkylene(cycloalkyl) or C 1 -C 6 alkylene(aryl); wherein the alkylene, cycloalkyl, and aryl, is optionally and independently substituted with one or more R 25a .

19. The compound of claim 1 , wherein each R 25a is independently halogen, —CN, —OH, —OR a , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

20. The compound of claim 1 , wherein each R 25a is independently halogen, —OH, —OR a , —NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

21. The compound of claim 1 , wherein R 16 is —C(═O)R 26 .

22. The compound of claim 1 , wherein R 26 is C 1 -C 6 alkylene(cycloalkyl) or C 1 -C 6 alkylene(aryl); wherein the alkylene, cycloalkyl, and aryl is optionally and independently substituted with one or more R 26a .

23. The compound of claim 1 , wherein each R 26a is independently halogen, —CN, —OH, —OR a , —NR c R d , —C(═O)R a , —C(═O)OR b , —C(═O)NR C R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

24. The compound of claim 1 , wherein each R 26a is independently halogen, —OH, —OR a , —NR c R d , C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.

25. A compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:

26. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and at least one pharmaceutically acceptable carrier.

27. A method of treating a viral infection, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

28. The method of claim 27 , further comprising administering at least one antiviral agent.

29. The method of claim 27 , wherein the viral infection is caused by a virus selected from the group consisting of coronavirus disease 2019 (SARS-CoV-2), Yellow Fever, Eastern Equine Encephalitis virus, Human Immunodeficiency virus (HIV), “African Swine Fever Viruses,” Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Astroviridae, Baculoviridae, Bimaviridae, Bimaviridae, Bunyaviridae, Caliciviridae, Caulimoviridae, Circoviridae, Coronaviridae, Cystoviridae, Ebolavirus, Deltaviridae, Filviridae, Filoviridae, Flaviviridae, Iridoviridae, Mononegavirus, Myoviridae, Papiloma virus, Papovaviridae, Paramyxoviridae, Prions, Parvoviridae, Phycodnaviridae, Poxyiridae, Potyviridae, Reoviridae, Retroviridae, Rhabdoviridae, Tectiviridae, Togaviridae, pox, papilloma, corona, influenza, sendai virus (SeV), sindbis virus (SINV), vaccinia viruses, West Nile, Hanta, viruses which cause the common cold, and any combination thereof.

30. The method of claim 27 , wherein the viral infection is caused by coronavirus disease 2019 (SARS-CoV-2) or a Ebolavirus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2022
From: BURNS, CHRISTOPHER J.; COBURN, GLEN; CHU, GUO-HUA; CONDON, STEPHEN M.; BOYD, STEVEN A.; PEVEAR, DANIEL C.
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 060279/0051 →
Continuity (5)
Continuation PCTUS2022033196 · Jun 13, 2022
Provisional Application 63210385 · Jun 14, 2021
Provisional Application 63257820 · Oct 20, 2021
Provisional Application 63328106 · Apr 6, 2022
Related Publication 20230024722A1 · Jan 26, 2023
Cited By (6)
US 12,297,226 US 12,357,577 US 12,404,289 US 12,448,383 US 12,509,466 US 12,655,172